A pleiotropic, posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa

L. J.V. Piddock, M. C. Hall, F. Bellido, M. Bains, Robert Hancock

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

An enoxacin-resistant Pseudomonas aeruginosa mutant (G49) isolated during patient therapy was characterized in detail. The G49 mutant was cross resistant to several classes of antibiotics including quinolones, β-lactams, chloramphenicol, and tetracycline, but not imipenem or aminoglycosides. Compared with its paired pretherapy isolate G48, this mutant had several alterations in outer membrane proteins including a complete loss of the major porin protein OprF and a substantially altered lipopolysaccharide profile. Revertants were selected at a frequency of approximately 1% after enrichment for OprF+ cells on low-salt proteose peptone no. 2 medium. Ninety-seven of these OprF+ revertants were as susceptible to carbenicillin and norfloxacin as the pretherapy isolate. One of these revertants was characterized in more detail and shown to be indistinguishable in all properties from the pretherapy isolate. It is proposed that the multiple-antibiotic-resistance (Mar) phenotype of this mutant resulted from a single pleiotropic mutation.

LanguageEnglish
Pages1057-1061
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Volume36
Issue number5
DOIs
Publication statusPublished - 1 Jan 1992
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Piddock, L. J.V. ; Hall, M. C. ; Bellido, F. ; Bains, M. ; Hancock, Robert. / A pleiotropic, posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa. In: Antimicrobial Agents and Chemotherapy. 1992 ; Vol. 36, No. 5. pp. 1057-1061.
@article{52f8c8013e2e4fd0a0f96c0ee45109d5,
title = "A pleiotropic, posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa",
abstract = "An enoxacin-resistant Pseudomonas aeruginosa mutant (G49) isolated during patient therapy was characterized in detail. The G49 mutant was cross resistant to several classes of antibiotics including quinolones, β-lactams, chloramphenicol, and tetracycline, but not imipenem or aminoglycosides. Compared with its paired pretherapy isolate G48, this mutant had several alterations in outer membrane proteins including a complete loss of the major porin protein OprF and a substantially altered lipopolysaccharide profile. Revertants were selected at a frequency of approximately 1{\%} after enrichment for OprF+ cells on low-salt proteose peptone no. 2 medium. Ninety-seven of these OprF+ revertants were as susceptible to carbenicillin and norfloxacin as the pretherapy isolate. One of these revertants was characterized in more detail and shown to be indistinguishable in all properties from the pretherapy isolate. It is proposed that the multiple-antibiotic-resistance (Mar) phenotype of this mutant resulted from a single pleiotropic mutation.",
author = "Piddock, {L. J.V.} and Hall, {M. C.} and F. Bellido and M. Bains and Robert Hancock",
year = "1992",
month = "1",
day = "1",
doi = "10.1128/AAC.36.5.1057",
language = "English",
volume = "36",
pages = "1057--1061",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
number = "5",

}

A pleiotropic, posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa. / Piddock, L. J.V.; Hall, M. C.; Bellido, F.; Bains, M.; Hancock, Robert.

In: Antimicrobial Agents and Chemotherapy, Vol. 36, No. 5, 01.01.1992, p. 1057-1061.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A pleiotropic, posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa

AU - Piddock, L. J.V.

AU - Hall, M. C.

AU - Bellido, F.

AU - Bains, M.

AU - Hancock, Robert

PY - 1992/1/1

Y1 - 1992/1/1

N2 - An enoxacin-resistant Pseudomonas aeruginosa mutant (G49) isolated during patient therapy was characterized in detail. The G49 mutant was cross resistant to several classes of antibiotics including quinolones, β-lactams, chloramphenicol, and tetracycline, but not imipenem or aminoglycosides. Compared with its paired pretherapy isolate G48, this mutant had several alterations in outer membrane proteins including a complete loss of the major porin protein OprF and a substantially altered lipopolysaccharide profile. Revertants were selected at a frequency of approximately 1% after enrichment for OprF+ cells on low-salt proteose peptone no. 2 medium. Ninety-seven of these OprF+ revertants were as susceptible to carbenicillin and norfloxacin as the pretherapy isolate. One of these revertants was characterized in more detail and shown to be indistinguishable in all properties from the pretherapy isolate. It is proposed that the multiple-antibiotic-resistance (Mar) phenotype of this mutant resulted from a single pleiotropic mutation.

AB - An enoxacin-resistant Pseudomonas aeruginosa mutant (G49) isolated during patient therapy was characterized in detail. The G49 mutant was cross resistant to several classes of antibiotics including quinolones, β-lactams, chloramphenicol, and tetracycline, but not imipenem or aminoglycosides. Compared with its paired pretherapy isolate G48, this mutant had several alterations in outer membrane proteins including a complete loss of the major porin protein OprF and a substantially altered lipopolysaccharide profile. Revertants were selected at a frequency of approximately 1% after enrichment for OprF+ cells on low-salt proteose peptone no. 2 medium. Ninety-seven of these OprF+ revertants were as susceptible to carbenicillin and norfloxacin as the pretherapy isolate. One of these revertants was characterized in more detail and shown to be indistinguishable in all properties from the pretherapy isolate. It is proposed that the multiple-antibiotic-resistance (Mar) phenotype of this mutant resulted from a single pleiotropic mutation.

UR - http://www.scopus.com/inward/record.url?scp=0026777171&partnerID=8YFLogxK

U2 - 10.1128/AAC.36.5.1057

DO - 10.1128/AAC.36.5.1057

M3 - Article

VL - 36

SP - 1057

EP - 1061

JO - Antimicrobial Agents and Chemotherapy

T2 - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 5

ER -